Clinical Trial Update: Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2b trial update for intravesical DTA-H19/PEI in intermediate-risk superficial bladder cancer has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer
• Superficial Bladder Cancer

Drugs mentioned

• DTA-H19/PEI (DTA-H19/PEI)

Snippet

Sponsor: Anchiano Therapeutics Israel Ltd. | Conditions: Superficial Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-08-21